UBS Group Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price

Moderna (NASDAQ:MRNA) had its target price decreased by UBS Group from $96.00 to $78.00 in a report released on Wednesday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other analysts also recently issued reports on the stock. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday. Leerink Partners reduced their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Finally, Evercore ISI reduced their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a report on Monday, January 27th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $60.63.

Moderna Price Performance

Shares of MRNA stock opened at $35.53 on Wednesday. The company has a market capitalization of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59. Moderna has a one year low of $29.25 and a one year high of $170.47. The company’s fifty day moving average price is $38.17 and its 200-day moving average price is $53.20.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of large investors have recently made changes to their positions in MRNA. Blue Trust Inc. boosted its position in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares during the period. Raymond James & Associates boosted its position in Moderna by 19.7% in the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after buying an additional 26,657 shares during the period. Eastern Bank boosted its position in Moderna by 2.3% in the 3rd quarter. Eastern Bank now owns 14,578 shares of the company’s stock valued at $974,000 after buying an additional 334 shares during the period. Bank Pictet & Cie Europe AG boosted its position in Moderna by 1.4% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 529,686 shares of the company’s stock valued at $35,399,000 after buying an additional 7,060 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its position in Moderna by 9.7% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 6,087 shares of the company’s stock valued at $407,000 after buying an additional 537 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.